JFG
QNCX icon

JDM Financial Group’s Quince Therapeutics QNCX Stock Holding History

JDM Financial Group’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18 Sell
1
-1
-50% -$23 ﹤0.01% 332
2026
Q1 		$34 Hold
2
– – ﹤0.01% 317
2025
Q4 		$1.14K Hold
2
– – ﹤0.01% 243
2025
Q3 		$554 Hold
2
– – ﹤0.01% 279
2025
Q2 		$561 Hold
2
– – ﹤0.01% 258
2025
Q1 		$452 Hold
2
– – ﹤0.01% 293
2024
Q4 		$636 Hold
2
– – ﹤0.01% 318
2024
Q3 		$264 Hold
2
– – ﹤0.01% 403
2024
Q2 		$255 Hold
2
– – ﹤0.01% 221
2024
Q1 		$360 Hold
2
– – ﹤0.01% 211
2023
Q4 		$357 Hold
2
– – ﹤0.01% 208
2023
Q3 		$381 Hold
2
– – ﹤0.01% 207
2023
Q2 		$512 Hold
2
– – ﹤0.01% 207
2023
Q1 		$530 Hold
2
– – ﹤0.01% 216
2022
Q4 		$217 Buy
+2
New +$334 ﹤0.01% 215

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JDM Financial Group's QNCX Position: Q2 2026 in Review

JDM Financial Group reduced its Quince Therapeutics (QNCX) stake by 50% in Q2 2026, selling an estimated $23 and leaving 1 share worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #332.

JDM Financial Group first reported a position in QNCX in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.14K in Q4 2025. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • JDM Financial Group held 1 share of Quince Therapeutics worth $18 as of Q2 2026.
  • JDM Financial Group sold 1 Quince Therapeutics share in Q2 2026, an estimated $23.
  • Quince Therapeutics made up ﹤0.01% of JDM Financial Group's portfolio in Q2 2026, its #332 holding.
  • JDM Financial Group first reported a position in Quince Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • JDM Financial Group's Quince Therapeutics position peaked at $1.14K in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on JDM Financial Group's 13F filing for Q2 2026, filed 18 Aug 2026.